Latest Treatment News in Neuroendocrine Tumours

Temozolomide Access in Ontario

CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to [...]

By |2021-07-07T21:48:16+00:00July 6th, 2021|Treatment News|Comments Off on Temozolomide Access in Ontario

Lutathera Funded in Saskatchewan

As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced [...]

By |2021-07-06T18:30:28+00:00July 6th, 2021|Treatment News|Comments Off on Lutathera Funded in Saskatchewan

LUTATHERA Funded In British Columbia

CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication. The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal Peptide [...]

By |2021-05-30T15:16:40+00:00March 8th, 2021|Treatment News|Comments Off on LUTATHERA Funded In British Columbia

LUTATHERA® Funded in Ontario

Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs). The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs [...]

By |2020-10-10T14:14:05+00:00October 10th, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Ontario

LUTATHERA® Funded in Quebec

As of September 30, 2020, the Québec Ministry of Health and Social Services has listed Lutathera on the Liste de Médicaments – Établissements. Lutathera will be reimbursed for GEP-NETs patients [...]

By |2020-10-03T15:46:51+00:00October 3rd, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Quebec

LUTATHERA® Funded in Nova Scotia

As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut [...]

By |2020-09-06T16:03:58+00:00September 4th, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Nova Scotia

New Delivery System for Somatuline® Autogel®

Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection) Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for [...]

By |2020-01-07T23:48:51+00:00January 7th, 2020|Treatment News|Comments Off on New Delivery System for Somatuline® Autogel®

68Ga-DOTATATE PET scan in Ontario

68Ga-DOTATATE PET scan in Ontario Cancer Care Ontario has announced that as of April 1st, 2019, Ontario patients with neuroendocrine tumours (NETs) meeting eligibility criteria are able to have [...]

By |2019-04-12T23:00:13+00:00April 12th, 2019|Treatment News|Comments Off on 68Ga-DOTATATE PET scan in Ontario

Health Canada approves XERMELO™ (telotristat ethyl)

Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1) "XERMELOTM is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase [...]

By |2018-10-17T14:45:09+00:00October 17th, 2018|Treatment News|Comments Off on Health Canada approves XERMELO™ (telotristat ethyl)
Go to Top